Metabolic Dysfunction-Associated Steatotic Liver Disease

Hepatic steatosis was prevalent among 52% of adults with or without type 2 diabetes and no known history of metabolic dysfunction-associated steatotic liver disease, according to findings published in Obesity.

The FDA granted breakthrough designation to Sagimet Biosciences’ denifanstat for the treatment of patients with metabolic dysfunction-associated steatohepatitis and moderate to advanced fibrosis, according to a company press release.

Every October marks Liver Cancer Awareness Month in an effort to raise awareness and improve advocacy and treatment for patients living with the disease.

Sodium-glucose cotransporter-2 inhibitors showed similar hepatic effectiveness to glucagon-like peptide-1 receptor agonists, especially among women and younger patients, in metabolic dysfunction-associated steatotic liver disease.

Use of glucagon-like peptide-1 receptor agonists was associated with a reduced risk for progression to cirrhosis and other complications in patients with metabolic dysfunction-associated steatotic liver disease and diabetes, data showed.

An intermittent calorie restriction diet was “safe and more effective” in reducing hepatic steatosis at 12 weeks vs. a standard of care diet in metabolic dysfunction-associated steatotic liver disease, particularly among those with obesity.

Vitamin E improved serum markers of liver inflammation and histology in patients with metabolic dysfunction-associated steatotic liver disease, according to results from a systematic review and meta-analysis.

With the FDA label for Rezdiffra excluding the need for liver biopsy, experts proposed recommendations to “fill the gap” on how to leverage noninvasive tests to assess treatment response in metabolic dysfunction-associated steatohepatitis.

Pemvidutide, a glucagon-like peptide-1/glucagon dual receptor agonist, lowered liver fat content, markers of inflammation and body weight in patients with metabolic dysfunction-associated steatotic liver disease and obesity, research showed.

A prediction model could be a “starting point” to identify patients with metabolic dysfunction-associated steatotic liver disease at high risk for hepatocellular carcinoma who may require intervention or surveillance, researchers wrote.